Q16539

PTMD Annotation Information


※ Protein Information

Tag Content
UniProt Accession MK14_HUMAN; Q16539;
Entrez ID 1432
GenBank Protein ID NM_001315.2; NM_139012.2; NM_139013.2; NM_139014.2;
GenBank Nucleotide ID NP_001306.1; NP_620581.1; NP_620582.1; NP_620583.1;
Protein Name Mitogen-activated protein kinase 14 (MAP kinase 14) (MAPK 14) (EC 2.7.11.24) (Cytokine suppressive anti-inflammatory drug-binding protein) (CSAID-binding protein) (CSBP) (MAP kinase MXI2) (MAX-interacting protein 2) (Mitogen-activated protein kinase p38 a
Gene Name MAPK14; CSBP; CSBP1; CSBP2; CSPB1; MXI2; SAPK2A
Organism Homo sapiens
NCBI Taxa ID 9606
Functional DescriptionSerine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK14 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. Some of the targets are downstream kinases which (view all)
Sequence
(Fasta)
MSQERPTFYR QELNKTIWEV PERYQNLSPV GSGAYGSVCA AFDTKTGLRV AVKKLSRPFQ 60
SIIHAKRTYR ELRLLKHMKH ENVIGLLDVF TPARSLEEFN DVYLVTHLMG ADLNNIVKCQ 120
KLTDDHVQFL IYQILRGLKY IHSADIIHRD LKPSNLAVNE DCELKILDFG LARHTDDEMT 180
GYVATRWYRA PEIMLNWMHY NQTVDIWSVG CIMAELLTGR TLFPGTDHID QLKLILRLVG 240
TPGAELLKKI SSESARNYIQ SLTQMPKMNF ANVFIGANPL AVDLLEKMLV LDSDKRITAA 300
QALAHAYFAQ YHDPDDEPVA DPYDQSFESR DLLIDEWKSL TYDEVISFVP PPLDQEEMES 360
361

※ PTM-Disease Association

NumPTMDiseaseCell TypeTypePTM SitePMID
1PhosphorylationPancreatic cancer/carcinoma/adenocarcinomaP23712777
[Reference]: DF-1 upregulation of MMP-2 is mediated by p38 MAPK signaling in pancreatic cancer cell lines
2PhosphorylationColon cancer/carcinomaP23799978
[Reference]: Flt-1 is required for PlGF-induced p38 phosphorylation and its results of promoting CRC cells migration/invasion
3PhosphorylationBreast cancer/tumor/carcinomacell lineP23539298
[Reference]: In breast cancer cells, EZH2 binds to phosphorylated p38 (p-p38) in association with other core members of the Polycomb repressive complex 2, EED, and SUZ12, and EZH2 overexpression leads to increased levels of p-p38 and of activated, downstream pathway proteins
4PhosphorylationLymphomacell lineP23620775
[Reference]: In vitro, sorafenib significantly decreased cell proliferation and phosphorylation levels of MAPK and PI3K/Akt pathways while increased apoptotic cell death
5PhosphorylationMelanomaP12114539
[Reference]: Infection with Ad.mda-7 increased the phosphorylation of p38 MAPK and heat shock protein 27 in melanoma cells but not in normal immortal melanocytes.
6PhosphorylationParkinson's diseaseU24405770
[Reference]: Compared with controls, no significant difference of total p38MAPK or JNK levels were observed in AD and PD patients, whereas phosphorylated p38MAPK and phosphorylated JNK levels were significantly increased in the AD and PD groups (p<0.001)
7PhosphorylationAlzheimer's diseaseU24405770
[Reference]: Compared with controls, no significant difference of total p38MAPK or JNK levels were observed in AD and PD patients, whereas phosphorylated p38MAPK and phosphorylated JNK levels were significantly increased in the AD and PD groups (p<0.001)
8PhosphorylationBipolar disorderU24075327
[Reference]: Western blot and flow cytometry analyses showed increased phosphorylation levels of p65 NF-B subunit, and MAPKs ERK1/2, and p38 in BD patients in euthymia in comparison with controls
9Threonine PhosphorylationLung cancer/carcinomaPT18022348039
[Reference]: The results showed that 18 molecules were significantly different (p<0.05) by at least 30% between normal and tumor tissues.
10Tyrosine PhosphorylationBreast cancer/tumor/carcinomaPY18223771849
[Reference]: rther study demonstrated that COX-2-induced radioresistance is negatively regulated through the phosphorylation of p38 at Tyr182, and that the phosphorylation of p38 induced by TNF-alpha reduces the expression of Bcl-2, BCL-XL, but increases -catenin and E-cadherin, leading to the decreased invasiveness of cells

※ Disease Cross-ref Annotation

DatabaseAnnotation
CTD (Curated)
(count: 6)
MESH:D009202 ; Cardiomyopathies
MESH:D002779 ; Cholestasis
MESH:D015464 ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive
MESH:D008113 ; Liver Neoplasms
MESH:D008175 ; Lung Neoplasms
MESH:D017202 ; Myocardial Ischemia
DisGeNet (Curated)
(count: 11)
(view all)
C0008370; Cholestasis
C0023473; Myeloid Leukemia, Chronic
C0023903; Liver neoplasms
C0024121; Lung Neoplasms
C0024809; Marijuana Abuse
C0036341; Schizophrenia
GWASdb
(count: 4)
rs17714205; Multiple complex diseases; Null
rs2237093; Multiple complex diseases; Null
rs2237093; Type 1 diabetes; type 1 diabetes mellitus
rs851006; Premature ovarian failure; premature ovarian failure

※ PTM Sites

PTM Modification Sites
Phosphorylation
(count: 16)
(view all)
123       IVKCQKLTDDHVQFL     dbPAF
16        YRQELNKTIWEVPER     dbPAF
175       DFGLARHTDDEMTGY     dbPAF
180       RHTDDEMTGYVATRW     dbPAF
182       TDDEMTGYVATRWYR     dbPAF
185       EMTGYVATRWYRAPE     dbPAF
Acetylation
(count: 3)
152       DIIHRDLKPSNLAVN     PLMD
233       TDHIDQLKLILRLVG     PLMD
53        TGLRVAVKKLSRPFQ     PLMD
Ubiquitination
(count: 12)
(view all)
121       NNIVKCQKLTDDHVQ     PLMD
139       YQILRGLKYIHSADI     PLMD
15        FYRQELNKTIWEVPE     PLMD
152       DIIHRDLKPSNLAVN     PLMD
233       TDHIDQLKLILRLVG     PLMD
248       TPGAELLKKISSESA     PLMD
Sumoylation
(count: 1)
79        LRLLKHMKHENVIGL     PLMD

※ Protein-Protein Interaction

NetworkInteraction
ABSource
O43257Q16539IntAct
O75582Q16539IntAct
O75676Q16539IntAct
O95295Q16539IntAct
P00747Q16539IntAct
P03372Q16539HPRD
P04637Q16539MINT
P06400Q16539IntAct; MINT
P09211Q16539IntAct
P10415Q16539HPRD
P15336Q16539MINT
P15822Q16539IntAct
P16220Q16539HPRD
P16452Q16539IntAct
P19419Q16539HPRD
P21333Q16539IntAct
P27361Q16539MINT;HPRD
P28482Q16539HPRD;MINT
P28562Q16539IntAct; MINT;HPRD
P29590Q16539HPRD
P30414Q16539IntAct
P35236Q16539MINT
P35268Q16539IntAct
P36537Q16539IntAct
P42224Q16539HPRD
P45983Q16539HPRD
P45985Q16539HPRD
P46734Q16539MINT
P49137Q16539IntAct;HPRD
P52564Q16539MINT
P52746Q16539IntAct
P53667Q16539MINT
P62945Q16539IntAct
P68104Q16539IntAct
P78352Q16539MINT
Q01082Q16539IntAct
Q02750Q16539HPRD
Q03188Q16539IntAct
Q04206Q16539MINT
Q06413Q16539IntAct
Q07352Q16539IntAct; MINT
Q08117Q16539IntAct
Q13243Q16539IntAct
Q13541Q16539HPRD
Q14318Q16539IntAct; MINT
Q14814Q16539IntAct
Q15256Q16539MINT
Q15750Q16539MINT
Q15759Q16539MINT
Q16512Q16539IntAct
Q16539Q16829MINT
Q16539Q1RMC8IntAct
Q16539Q49A88IntAct
Q16539Q5JSJ4IntAct
Q16539Q5T3F8IntAct
Q16539Q6IN85IntAct
Q16539Q6PJG2IntAct
Q16539Q7Z3C6MINT
Q16539Q86TA1IntAct
Q16539Q8IW41IntAct
Q16539Q8NEM7IntAct
Q16539Q8NEZ4IntAct
Q16539Q92574IntAct
Q16539Q92905IntAct
Q16539Q96F63IntAct
Q16539Q96G01IntAct
Q16539Q96RR4IntAct
Q16539Q99626HPRD
Q16539Q99956MINT
Q16539Q99988IntAct
Q16539Q9BRR9IntAct
Q16539Q9BUB5IntAct
Q16539Q9BY84IntAct
Q16539Q9H869IntAct
Q16539Q9HBH9IntAct
Q16539Q9NQU5MINT
Q16539Q9UGU0IntAct
Q16539Q9UKN1IntAct
Q16539Q9UPV0IntAct
Q16539Q9Y4K3HPRD
Q16539Q9Y6Q9MINT
Q16539Q9Y6W6IntAct